Among SMEs, the HTA Regulation alters how evidence reaches decision makers and shapes subsequent reimbursement decisions across Europe. Health economics teams must reassess how they prepare submissions under tighter procedural windows while preserving credible value arguments for national payers.
Thirteen Joint Clinical Assessments began in the first year, confirming that parallel regulatory and clinical review timelines are workable. Yet smaller organisations frequently lack internal health economics capacity and must therefore engage external specialists at considerable cost. These added expenses compress development budgets and may delay the generation of data needed for robust pricing strategies.
Consequences for Value Assessment and Reimbursement Decisions
When PICO scoping fails to consolidate fully, companies confront multiple overlapping evidence requirements. This multiplies workload without delivering the intended efficiency, directly affecting budget impact calculations that health systems rely upon. Payers may consequently receive assessments containing residual uncertainty, prompting more conservative reimbursement decisions or demands for further data collection after launch.
A functioning Joint Clinical Assessment process could shorten the interval between authorisation and multi-country coverage, improving predictability for companies targeting smaller markets. Conversely, persistent capacity limits on early scientific advice risk pushing SMEs toward narrower launch sequences that concentrate initially on larger economies, distorting equitable access and complicating system-wide budget planning.
Actionable Steps for Companies and Assessment Bodies
Market access directors should map internal evidence generation plans against emerging methodological guidance at least eighteen months before pivotal trial read-outs. HTA bodies can support this by publishing clear prioritisation criteria for Joint Scientific Consultation slots and by offering streamlined templates tailored to organisations with limited staff. Value-based pricing negotiations will benefit when companies can reference a single, high-quality clinical assessment rather than repeated national reviews.
Monitoring and Adaptive Governance
Independent evaluation must track not only procedural metrics but also downstream effects on launch patterns and overall cost-effectiveness. Health systems that integrate these assessments into existing budget impact models early will be better placed to accommodate new therapies without destabilising annual planning cycles. European Commission coordination remains essential to prevent fragmentation that could otherwise raise total expenditure on evidence synthesis across Member States.
SMEs will continue to be test case whether the framework accelerates or impedes therapeutic innovation in areas of high unmet need. Decision makers who invest now in aligned processes and targeted support mechanisms stand to improve both patient access and long-term system sustainability.
Bibliography
- European Commission. Joint Clinical Assessments. Health Technology Assessment section. https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment/joint-clinical-assessments_en (accessed July 2026).
- European Commission. HTA Coordination Group publishes its 2025 Annual Report (February 2026). https://ec.europa.eu/newsroom/sante/newsletter-archives/72152.
- EuropaBio. Joint Industry Statement on JSC Capacity (December 2024). https://www.europabio.org/joint-industry-statement-on-jsc-capacity/.
- Main C. et al. “From Vision to Reality: The EU’s Pharmaceutical Reforms and Health Technology Assessment Regulation.” PMC (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12037959/.
Table of Contents
